Drug Development Pharma - August 6, 2014
Boehringer Ingelheim returns project to Orexo
Orexo has announced that Boehringer Ingelheim has decided to return the OX-MPI project to Orexo. The project aims to develop products based on specific inhibition of prostaglandin E2 (PGE2) in different disease conditions. Since 2005, Boehringer Ingelheim has been responsible for all research and development within the project. Orexo will evaluate the results from Boehringer Ingelheim. When […]
Drug Development Pharma - August 4, 2014
Medivir licenses respiratory syncytial virus drug program
The company has entered a license agreement with Boehringer Ingelheim International GmbH for exclusive, global rights to a drug program for the treatment and prevention of RSV infection. The program includes novel compounds that inhibit the RSV fusion protein, which is a key mediator of viral entry into host cells and a target for new […]